title: Recombinant high-density lipoproteins and their use in cardiovascular diseases.
abstract: The unique anti-atherosclerosis abilities and other cardioprotective properties make high-density lipoprotein (HDL) a promising solution in treating cardiovascular diseases. A number of studies showed that HDL-based therapy was well tolerated and has great potential in the future. Among all these new agents, the most studied ones including recombinant HDL, recombinant human apolipoproteins, apolipoprotein mimetic peptides and recombinant HDL used as contrast agents in cardiovascular imaging are discussed here. Recombinant HDL and apolipoproteins are promising in diagnosing and treating cardiovascular diseases.
authors: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, China.
authors: Yi-Ni
authors: YN
authors: Cao
authors: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, China.
authors: Lu
authors: L
authors: Xu
authors: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, China.
authors: Ying-Chun
authors: YC
authors: Han
authors: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, China.
authors: Yu-Nan
authors: YN
authors: Wang
authors: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, China.
authors: George
authors: G
authors: Liu
authors: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, China. Electronic address: ronaqi@bjmu.edu.cn.
authors: Rong
authors: R
authors: Qi
mesh_terms: D000818:Animals; D016632:Apolipoprotein A-I / Q000627:therapeutic use; D040761:Biomimetic Materials / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D015195:Drug Design; D006801:Humans; D008075:Lipoproteins, HDL / Q000235:genetics / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D016632:Apolipoprotein A-I; D002316:Cardiotonic Agents; D008075:Lipoproteins, HDL; D010455:Peptides; D011994:Recombinant Proteins